Retraction Note: Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.

IF 6.8 1区医学 Q1 ONCOLOGY

British Journal of Cancer Pub Date : 2025-09-25 DOI:10.1038/s41416-025-03214-y

V Damiano, R Rosa, L Formisano, L Nappi, T Gelardi, R Marciano, I Cozzolino, G Troncone, S Agrawal, B M Veneziani, S De Placido, R Bianco, G Tortora

引用次数: 0

查看原文本刊更多论文

注：toll样受体9激动剂IMO通过干扰肿瘤生长和血管生成与依维莫司合作治疗肾细胞癌。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Cancer 医学-肿瘤学

CiteScore

15.10

自引率

1.10%

发文量

383

审稿时长

6 months

期刊介绍： The British Journal of Cancer is one of the most-cited general cancer journals, publishing significant advances in translational and clinical cancer research.It also publishes high-quality reviews and thought-provoking comment on all aspects of cancer prevention,diagnosis and treatment.